Background: Non-tuberculous mycobacterial (NTM) pulmonary disease (PD) is a significant concern in China, compounding the existing burden of TB. This review aims to summarise the treatment outcomes for NTM-PD in China.
Methods: We reviewed the evidence on NTM-PD, including treatment regimens and clinical outcomes, from 17 studies identified through screening of three Chinese biomedical databases.
Results: Antimicrobial treatment showed a microbiological cure rate ranging from 17.2% to 60.0% in studies with ≥50 NTM-PD patients, with lower rates observed among older and malnourished patients. The abscessus group (MC-AG) and -intracellulare complex (MAC) were the most prevalent NTM species in China. Higher microbiological cure rates were seen in MAC PD compared with MC-AG PD. The addition of cefoxitin and linezolid improved culture conversion rates in MC-AG-infected patients. One study ( = 24) demonstrated that resecting lesions and chemotherapy led to more favourable clinical outcomes.
Conclusion: Treatment regimens recommended in Chinese guidelines yielded poor-to-moderate outcomes for NTM-PD in China, highlighting the need for further research into alternative antimicrobial treatments to improve efficacy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11636495 | PMC |
| http://dx.doi.org/10.5588/ijtldopen.24.0413 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cough and sputum symptoms reduce physical activity in patients with NTM pulmonary disease.
Int J Tuberc Lung Dis
January 2025
Department of Physical Therapy Science, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Non-Tuberculous Mycobacteria: Single Center Analyses of Risk Factors, Management and Mortality Outcomes of Adults with HIV.
Diagnostics (Basel)
November 2024
Department of Internal Medicine, University of Witwatersrand, Johannesburg 2193, South Africa.
Background/objectives: In sub-Saharan Africa, there is paucity of data regarding non-tuberculous mycobacterial (NTM) infections, leading to underappreciation of disease burden. Consequently, fewer resources are allocated, leading to potential adverse outcomes. This study examines long-term mortality and risk factors of South African patients with positive NTM samples.
View Article and Find Full Text PDFTreatment outcomes in NTM-PD in a high TB burden context.
IJTLD Open
December 2024
GSK, Brentford, UK.
Background: Non-tuberculous mycobacterial (NTM) pulmonary disease (PD) is a significant concern in China, compounding the existing burden of TB. This review aims to summarise the treatment outcomes for NTM-PD in China.
Methods: We reviewed the evidence on NTM-PD, including treatment regimens and clinical outcomes, from 17 studies identified through screening of three Chinese biomedical databases.
Preliminary investigation of the significance of cavitary lesions in recurrent hemoptysis following bronchial artery embolization for nontuberculous mycobacterial pulmonary disease.
Respir Investig
November 2024
Department of Respiratory Medicine, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku, Tokyo, 162-8655, Japan.
Background: Nontuberculous mycobacterial pulmonary disease (NTM-PD) varies widely in clinical presentation, and some patients experience hemoptysis. Bronchial artery embolization (BAE) is a treatment option for hemoptysis caused by NTM-PD. However, the association between post-BAE rebleeding risk and the presence of cavitary lesions has not been fully elucidated.
View Article and Find Full Text PDFNationwide evaluation of treatment outcomes and survival of patients with non-tuberculous mycobacterial pulmonary disease.
Int J Tuberc Lung Dis
October 2024
Radboud Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!